Amedisys Inc (NASDAQ:AMED) Holdings Lifted by Timpani Capital Management LLC

Share on StockTwits

Timpani Capital Management LLC boosted its stake in shares of Amedisys Inc (NASDAQ:AMED) by 117.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,817 shares of the health services provider’s stock after purchasing an additional 11,237 shares during the period. Timpani Capital Management LLC owned 0.06% of Amedisys worth $2,566,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc increased its stake in Amedisys by 14.3% during the 3rd quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after purchasing an additional 415,060 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of Amedisys by 107.4% in the fourth quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock worth $56,000 after acquiring an additional 247 shares during the period. Bank of Montreal Can increased its stake in shares of Amedisys by 2.4% in the fourth quarter. Bank of Montreal Can now owns 21,048 shares of the health services provider’s stock worth $2,464,000 after acquiring an additional 487 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Amedisys by 15.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock worth $223,000 after buying an additional 251 shares in the last quarter. Finally, Arizona State Retirement System boosted its holdings in Amedisys by 6.3% during the fourth quarter. Arizona State Retirement System now owns 44,689 shares of the health services provider’s stock worth $5,234,000 after buying an additional 2,663 shares in the last quarter. Institutional investors own 86.30% of the company’s stock.

AMED has been the subject of a number of recent research reports. ValuEngine downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. Raymond James raised shares of Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 target price for the company in a research report on Thursday, May 2nd. Barclays increased their target price on Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, March 21st. BidaskClub upgraded Amedisys from a “sell” rating to a “hold” rating in a research note on Wednesday, June 5th. Finally, SunTrust Banks raised their price objective on Amedisys to $145.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $129.89.

In related news, Director Jeffrey A. Rideout sold 3,657 shares of Amedisys stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $116.03, for a total value of $424,321.71. Following the transaction, the director now owns 5,554 shares of the company’s stock, valued at approximately $644,430.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David L. Kemmerly sold 5,000 shares of Amedisys stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $118.20, for a total value of $591,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,168 shares of company stock worth $3,456,343. 2.90% of the stock is owned by corporate insiders.

Shares of AMED opened at $117.60 on Wednesday. The firm has a market cap of $3.71 billion, a PE ratio of 32.40, a price-to-earnings-growth ratio of 1.44 and a beta of 1.40. Amedisys Inc has a one year low of $80.01 and a one year high of $140.91. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.69.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.22. The firm had revenue of $467.34 million for the quarter, compared to analyst estimates of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. Amedisys’s revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.79 earnings per share. Sell-side analysts anticipate that Amedisys Inc will post 4.08 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Tech Know Bits and is the property of of Tech Know Bits. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://techknowbits.com/2019/06/12/timpani-capital-management-llc-buys-11237-shares-of-amedisys-inc-amed.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Recommended Story: NASDAQ Stock Market Explained

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.